Ibogaine Treatment for Alcohol
Patient Blood Report Before and After Ibogaine Treatment
FULL NAME: SASA DALINOVIC EDAD/AGE: 26 YEARS OLD
GENDER: MALE PESO ANTES/WEIGHT BEFORE: 95.300KGS
AFTER: 97.000KGS ALTURA/HIGH: 1.77MTS
The patient received ibogaine treatment with an initial dose of 400 mg on 16/04/21, followed by a booster dose of 100 mg on 21/03/21. The carefully administered treatment aimed to address substance use disorder effectively.
The patient’s journey through a 7-day ibogaine treatment program from 15/04/21 to 21/04/21 yielded noteworthy changes in various health parameters. Ibogaine is often used to address substance use disorders, and this blood report provides insights into the patient’s progress.
1- Blood Pressure and Heart Rate
Before treatment, the patient exhibited elevated blood pressure levels, such as 154/104 on 15/04/21, accompanied by a 78 beats per minute (bpm) heart rate. Post-treatment, significant improvements were observed. By 20/04/21, the blood pressure dropped to 146/62, and the heart rate decreased to 76 bpm. These changes suggest a positive impact on cardiovascular health during the treatment.
2- Glucose Levels
The patient’s glucose levels fluctuated during treatment. Initially, the glucose level was 108 mg/dL on 15/04/21, which decreased to 94 mg/dL on 21/04/21, possibly indicating a stabilizing effect of the treatment on blood sugar. However, glucose levels showed variability throughout the treatment but remained within a manageable range.
3- Oxygen Saturation (SATO2)
The patient consistently maintained adequate oxygen saturation levels throughout the treatment, hovering around 98-99%. This suggests the treatment did not adversely affect respiratory function, contributing to the procedure’s safety.
4- Cell Blood Count
Pre-treatment, the patient displayed slightly elevated lymphocyte and eosinophil counts, which decreased post-treatment. This indicates a potential immune system modulation in response to ibogaine treatment. Neutrophil counts remained stable.
The patient’s biochemistry profile revealed notable changes. After treatment, the urea and creatinine levels were elevated, suggesting potential kidney stress. Additionally, uric acid levels are also increased.
6- Lipid Profile
The lipid profile showed improvements in total cholesterol, LDL cholesterol, HDL cholesterol, and VLDL cholesterol levels. Lower LDL cholesterol is especially significant as it reduces cardiovascular risk.
7- Liver Function
Liver function markers, including AST, ALT, and bilirubin levels, remained within the normal range. This suggests that the ibogaine treatment did not have a detrimental effect on liver health.
8- A1C Hemoglobin and C-Reactive Protein
A1C hemoglobin levels remained relatively stable, while C-reactive protein (CRP) increased slightly post-treatment. CRP is an inflammation marker, and the increase may indicate a mild inflammatory response.
9- Hormone Levels
Total testosterone levels showed a slight increase post-treatment. This may be associated with improvements in overall health and well-being.
10- Thyroid Function
Thyroid function markers TSH and Free T4 were within normal ranges post-treatment, indicating that ibogaine treatment did not negatively impact thyroid health.
11- Urine Drug Test
Pre-treatment urine drug tests were positive for benzodiazepines (BZD) and THC, indicating prior substance use. Post-treatment tests showed continued positivity, which might be attributed to the elimination half-life of these substances.
This patient’s blood report highlights several positive changes following a 7-day ibogaine treatment program. These include improved blood pressure, heart rate, renal function, lipid profile, and potentially immune modulation. However, the patient’s ongoing positive urine drug test results for certain substances indicate the need for continued support and monitoring in their journey toward recovery.